Home Alzheimer’s Disease First-Line Nivolumab/Ipilimumab and 2 Chemo Cycles Provide Superior OS Vs Chemo Alone...

First-Line Nivolumab/Ipilimumab and 2 Chemo Cycles Provide Superior OS Vs Chemo Alone in Advanced NSCLC

Nivolumab (Opdivo) plus ipilimumab (Yervoy) and 2 cycles of chemotherapy provided superior overall survival (OS) results compared with chemotherapy alone as well as a favorable risk-benefit profile among patients with advanced non–small cell lung cancer (NSCLC), regardless of PD-L1 expression or histology, according to findings from a preplanned interim analysis and exploratory longer-term follow-up analysis from the phase 3 CheckMate 9LA trial (NCT03215706).

Investigators indicated that these data, published in The Lancet Oncology, support the use of this regimen as a new first-line treatment for this patient population. Of note, this study remains active, though it is no longer recruiting patients.

“As the study is still maturing (60% maturity in this report), longer follow-up will provide further characterization of the risk–benefit profile of nivolumab plus ipilimumab…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Third COVID-19 Vaccine Earns Emergency Use Authorization Following Favorable Advisory Committee Meeting

The first single-dose COVID-19 vaccine was granted Emergency Use Authorization (EUA) by the FDA, according to its developer Janssen Pharmaceutical Companies of Johnson &...

Abiraterone Acetate, Apalutamide Likeliest to Improve Survival for Patients with Castration-Sensitive Prostate Cancer

In a comparison of systemic treatments as add-ons to androgen-deprivation therapy (ADT) for patients with metastatic castration-sensitive prostate cancer (mCSPC), abiraterone acetate (Zytiga) and...

Women of Minority Race/Ethnicity, Lower Socioeconomic Status Experience Lower Digital Breast Tomosynthesis Access

A cross-sectional study of digital breast tomosynthesis (DBT) screening published in JAMA Network Open indicated that women of minority race/ethnicity and lower socioeconomic status...

Michael Szarek, PhD, on the Outcomes of a Q-TWiST Analysis From the Phase 3 TIVO-3 Study

An analysis revealed that as a third- or fourth-line treatment for RCC, tivozanib significantly increased Q-TWiST compared with sorafenib, primarily through an increase in...

Recent Comments